Literature DB >> 24866990

OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory.

Andrew J Graves1, Marcelino G Padilla, David A Hokey.   

Abstract

Entities:  

Keywords:  FACS; ICS; OMIP; T cell; T-cell memory; cytokine staining; cytometry; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24866990      PMCID: PMC4231567          DOI: 10.1002/cyto.a.22478

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


× No keyword cloud information.

Purpose and Appropriate Sample Types

This flow cytometry antibody panel was developed and optimized for the characterization of CD4+ and CD8+ T-cell memory and functional responses in adult and infant cryopreserved peripheral blood mononuclear cells (PBMC) stimulated with peptide pools to various antigens of interest (Table1). The panel has been used to evaluate Mycobacterium tuberculosis (TB) antigen-specific responses in clinical trial specimens, and is currently undergoing assay qualification.
Table 1

Summary table for application of OMIP-022

PurposeT-cell phenotyping, memory categorization, cytokine production, and function following in vitro stimulation
SpeciesHuman
Cell typesCryopreserved PBMC (adult and infant)
Cross referencesOMIP-001, OMIP-008, OMIP-009, and OMIP-014
Summary table for application of OMIP-022

Background

The lack of a correlate of immunity is a source of frustration in TB research 1. As such, it is crucial for TB vaccine researchers to “cast a wide net” when assessing immune responses to clinical trial candidates while minimizing the amount of specimen required to generate these data. This panel (Table2) began as an incremental enhancement to OMIP-014 2, and included markers for dump (fixable viability dye, CD14, and CD19), T-cell phenotype (CD3, CD4, and CD8), Th1 cytokines (IFN-γ and TNF), a Th2 cytokine (IL-4), T-cell proliferation cytokine (IL-2), degranulation (CD107a), and activation (CD154). We have also expanded the panel to include memory markers (CCR7 and CD45RO), a Th17 cytokine (IL-17A), and an IL-10 superfamily cytokine (IL-22, used in place of IL-4).
Table 2

Reagents used for OMIP-022

SpecificityCloneFluorochromePurpose
Viability DyeAViDDump
CD14M5E2V500
CD19HIB19V500
CD3UCHT1ECDPhenotype
CD4RPA-T4APC-eFluor 780
CD8HIT8aAx700
CCR7G043H7BV605Memory
CD45ROUCHL1BV785
IFN-γB27V450Th1
IL-2MQ1–17H12PE
TNFMAb11PE-Cy7
IL-17ABL168PerCP-Cy5.5Th17
IL-22IL22JOPAPCTh22
CD107aH4A3Ax488Degranulation
CD154TRAP1PE-Cy5Activation/B-Cell Help
Reagents used for OMIP-022 We chose to combine viability dye and dump markers on the same channel using AViD and V500 (for CD14 and CD19), thus freeing additional channels on the violet laser. For phenotyping, CD3 remains on ECD and CD4 on APC-eFluor 780. Th1 cytokines have been shown to be critical for controlling TB 3–9. To assess Th1 responses, we utilize antibodies against tumor necrosis factor (TNF) and IFN-γ. In designing this panel, we moved TNF to PE-Cy7 to improve detection of this cytokine, as fluorescein isothiocyanate (FITC) is comparatively dimmer and more prone to photobleaching. The recently introduced Brilliant Violet series of fluorochromes represents a bright and economical set of tools for detecting markers via the violet laser. Brilliant Violet 421 (BV421) was previously shown to be of similar brightness to PE 10, and was initially chosen as a replacement fluorochrome for IFN-γ. However, further investigation showed that any increase in antigen-specific response detected using the BV421 conjugate was matched with a significant increase in IFN-γ background. This increased background was observed using both the B27 (BD Biosciences, San Jose, CA) and the 4S.B3 (Biolegend, San Diego, CA) clones. When this background population was excluded from the IFN-γ gate of the BV421 conjugates, the responses detected using either the BV421 conjugates or the V450 conjugate were similar. This issue, combined with the increased cost of the reagent, led us to choose to continue to use the V450 conjugate for IFN-γ detection in this panel. Interleukin-2 (IL-2) is a cytokine responsible for T-cell proliferation and differentiation 11,12 that also may play a role in TB immunity 13. In our panel, we use PE for bright and efficient detection of this cytokine. As M. tuberculosis is a facultative intracellular bacteria, cytolytic activity may be necessary to help control the disease. CD107a (LAMP-1) is a marker for degranulation and an indirect marker for cytolytic function 14,15. Ideally, lytic proteins such as Perforin would be costained with the CD107a to confirm the cytotoxic potential of the CD107a+ cells. To this point, we are examining future iterations of this panel that may include a lytic marker. However, the current constraints of this panel limit our ability to add an additional marker without harming sensitivity in detecting the other markers of interest. To accommodate the change in fluorochrome for the detection of TNF, we moved CD107a to FITC initially, and then replaced FITC with the enhanced stability of Alexa Fluor 488 (Ax488). The Brilliant Violet series of fluorochromes has also allowed us to include the memory markers CCR7 and CD45RO. CCR7 is responsible for homing T-cells to lymph nodes 16 and is expressed on naïve and central memory T-cells (TCM) 17. CD45RO is the smallest isoform of CD45, and has been shown to be expressed on effector memory (TEM) and TCM 18. The inclusion of both markers allows for T-cells to be categorized as naïve, TCM, TEM, or effector T-cells. We chose Brilliant Violet 605 for CCR7 as it was the next brightest available Brilliant Violet dye and CCR7 is expressed as a continuum (not distinct populations) 19. The binding kinetics of the CCR7 antibody has shown optimal staining when incubated at 37°C (see staining protocol in Supporting Information). Brilliant Violet 785 was chosen for CD45RO based on antibody availability and minimal spectral overlap to other markers. IL-17A is secreted by Th17 T helper cells and acts to recruit innate immune effector cells to the site of inflammation 20. Recent works 21,22 have suggested a strong role for IL-17A in tuberculosis immunity. As such, we initially replaced the MIP-1β from OMIP-014 with and anti-IL-17A antibody. In our hands, the PerCP-Cy5.5 on CD8 causes high spectral overlap into the Ax700 channel used for IL-17A. As IL-17A is lowly expressed compared to CD8 (and as PerCP-Cy5.5 is fluorescently brighter), we exchanged the fluorochromes for these two markers to minimize the impact of the high compensation. As an effect of changing CD8 to Ax700, a reduction in CD8+ events [perhaps an escapee phenomenon 23] was noted using Ax700 to detect CD8, but was mitigated by staining for CD8 intracellularly. IL-4, previously included with OMIP-014, is a representative Th2 cytokine. This interleukin is extremely difficult to detect and, in our hands, is inconsistent. We continue to include this marker as an option when assessing clinical trial specimens in which Th2 is considered a desired response. Recently, however, we have substituted IL-22 on APC instead of IL-4. IL-22 is part of the IL-10 superfamily 24, and when coexpressed with IL-17 enhances production antimicrobial peptides in the mucosa 25. Although poorly characterized to this point, recent research indicates that IL-22 plays a role in TB infection 21,26. CD154 was maintained on this panel as emerging evidence indicates its role as a specific and sensitive marker in detecting CD4 response 27, as well as its roles in upregulating antimicrobial peptides 28 and its necessity for T-cell activation of B cells 29. As indicated in OMIP-014, the inclusion of Brefeldin A in our stimulation protocol requires intracellular staining of CD154. Figure 1 shows an example staining and analysis for adult PBMC stimulated with Staphylococcal enterotoxin B (Fig. 1A) or CMV pp65 (Fig. 1B).
Figure 1

Example staining of adult human PBMC following stimulation. (A) The first two rows demonstrate the gating hierarchy from total sample to CD4/CD8 identification. A time gate is used to exclude pressure aberrations from the cytometer that may have occurred during sample acquisition. Aggregate gates are used to exclude brightly positive events that may result from antibody or cell aggregation. The bottom row demonstrates gating for cytokines and functions from CD4+ (top half) and CD8+ (bottom half) events resulting from stimulation with Staphylococcal enterotoxin B. Note that IL-17A and CD154 were gated on the same plot to avoid mischaracterization resulting from the increased spectral overlap observed from their fluorochromes. (B) Example plots showing memory profile of CCR7 versus CD45RO in CD4+ and CD8+ populations. Using CMV pp65 peptide pool-stimulated PBMC from a CMV-reactive donor, IFN-γ+ events (blue) were overlaid onto these plots (gray), confirming localization of these events to the effector memory and effector compartments.

Example staining of adult human PBMC following stimulation. (A) The first two rows demonstrate the gating hierarchy from total sample to CD4/CD8 identification. A time gate is used to exclude pressure aberrations from the cytometer that may have occurred during sample acquisition. Aggregate gates are used to exclude brightly positive events that may result from antibody or cell aggregation. The bottom row demonstrates gating for cytokines and functions from CD4+ (top half) and CD8+ (bottom half) events resulting from stimulation with Staphylococcal enterotoxin B. Note that IL-17A and CD154 were gated on the same plot to avoid mischaracterization resulting from the increased spectral overlap observed from their fluorochromes. (B) Example plots showing memory profile of CCR7 versus CD45RO in CD4+ and CD8+ populations. Using CMV pp65 peptide pool-stimulated PBMC from a CMV-reactive donor, IFN-γ+ events (blue) were overlaid onto these plots (gray), confirming localization of these events to the effector memory and effector compartments.

Similarity to Published OMIPs

As this panel assesses antigen-specific T-cell responses, it is similar to OMIP-001 30, OMIP-008 31, OMIP-009 32, and OMIP-014 2. Furthermore, this panel evolved from an initial desire to implement OMIP-014. Unlike these panels, however, our panel includes T-cell memory markers as well as an extensive combination of cytokines and functions associated with tuberculosis vaccine research. Our panel was developed for use in multicenter studies under good clinical laboratory practices conditions, and is currently undergoing assay qualification.
  32 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

3.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

4.  The interleukin-2 T-cell system: a new cell growth model.

Authors:  D A Cantrell; K A Smith
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

Review 5.  Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway.

Authors:  D A Lammas; J L Casanova; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

6.  The interleukin-10 family of cytokines.

Authors:  Helmut Fickenscher; Simon Hör; Heide Küpers; Andrea Knappe; Sabine Wittmann; Heinrich Sticht
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

7.  Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1).

Authors:  M Merkenschlager; P C Beverley
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

Review 8.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

9.  Identification of two lysosomal membrane glycoproteins.

Authors:  J W Chen; T L Murphy; M C Willingham; I Pastan; J T August
Journal:  J Cell Biol       Date:  1985-07       Impact factor: 10.539

10.  Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis.

Authors:  Z Toossi; M E Kleinhenz; J J Ellner
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  8 in total

1.  OMIP-025: evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining.

Authors:  Gemma Moncunill; Carlota Dobaño; M Juliana McElrath; Stephen C De Rosa
Journal:  Cytometry A       Date:  2014-11-18       Impact factor: 4.355

2.  Multiparameter Flow Cytometry for Detailed Characterization of Peritoneal Immune Cells from Patients with Ovarian Cancer.

Authors:  Jessica Vazquez; Dagna Sheerar; Aleksandar K Stanic; Manish S Patankar
Journal:  Methods Mol Biol       Date:  2022

3.  Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Authors:  A J Graves; D A Hokey
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Authors:  Rhea N Coler; Tracey A Day; Ruth Ellis; Franco M Piazza; Anna Marie Beckmann; Julie Vergara; Tom Rolf; Lenette Lu; Galit Alter; David Hokey; Lakshmi Jayashankar; Robert Walker; Margaret Ann Snowden; Tom Evans; Ann Ginsberg; Steven G Reed
Journal:  NPJ Vaccines       Date:  2018-09-04       Impact factor: 7.344

5.  CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.

Authors:  Tereza Masonou; David A Hokey; Timothy Lahey; Alice Halliday; Luis C Berrocal-Almanza; Wendy F Wieland-Alter; Robert D Arbeit; Ajit Lalvani; C Fordham von Reyn
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

6.  Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.

Authors:  Virginie Rozot; Elisa Nemes; Hennie Geldenhuys; Munyaradzi Musvosvi; Asma Toefy; Frances Rantangee; Lebohang Makhethe; Mzwandile Erasmus; Nicole Bilek; Simbarashe Mabwe; Greg Finak; William Fulp; Ann M Ginsberg; David A Hokey; Muki Shey; Sanjay Gurunathan; Carlos DiazGranados; Linda-Gail Bekker; Mark Hatherill; Thomas J Scriba
Journal:  Commun Biol       Date:  2020-10-09

7.  A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

Authors:  Sharon Sheehan; Stephanie A Harris; Iman Satti; David A Hokey; Veerabadran Dheenadhayalan; Lisa Stockdale; Zita-Rose Manjaly Thomas; Alice Minhinnick; Morven Wilkie; Samantha Vermaak; Joel Meyer; Matthew K O'Shea; Maria Grazia Pau; Isabella Versteege; Macaya Douoguih; Jenny Hendriks; Jerald Sadoff; Bernard Landry; Paul Moss; Helen McShane
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

8.  Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.

Authors:  Justin Pollara; R Whitney Edwards; Shalini Jha; Chia-Ying Kao Lam; Liqin Liu; Gundo Diedrich; Jeffrey L Nordstrom; Tori Huffman; Joy A Pickeral; Thomas N Denny; Sallie R Permar; Guido Ferrari
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.